Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 29 April 1994:
Vol. 264. no. 5159, pp. 716 - 719
DOI: 10.1126/science.7513441
Prev | Table of Contents | Next

Articles

Science, Vol 264, Issue 5159, 716-719
Copyright © 1994 by American Association for the Advancement of Science

articles

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines

AL Cox, J Skipper, Y Chen, RA Henderson, TL Darrow, J Shabanowitz, VH Engelhard, DF Hunt, and CL Slingluff Jr

Department of Chemistry, University of Virginia, Charlottesville 22908.

Of several thousand peptides presented by the major histocompatibility molecule HLA-A2.1, at least nine are recognized by melanoma-specific cytotoxic T lymphocytes (CTLs). Tandem mass spectrometry was used to identify and to sequence one of these peptide epitopes. Melanoma-specific CTLs had an exceptionally high affinity for this nine-residue peptide, which reconstituted an epitope for CTL lines from each of five different melanoma patients tested. Recognition by multiple CTL lines suggests that this may be a promising candidate for use in peptide-based melanoma vaccines.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Steric Hindrance and Fast Dissociation Explain the Lack of Immunogenicity of the Minor Histocompatibility HA-1Arg Null Allele.
E. Spierings, S. Gras, J.-B. Reiser, B. Mommaas, M. Almekinders, M. G. D. Kester, A. Chouquet, M. Le Gorrec, J. W. Drijfhout, F. Ossendorp, et al. (2009)
J. Immunol. 182, 4809-4816
   Abstract »    Full Text »    PDF »
Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4.
O. Klein, L. M. Ebert, T. Nicholaou, J. Browning, S. E. Russell, M. Zuber, H. M. Jackson, N. Dimopoulos, B. S. Tan, A. Hoos, et al. (2009)
Clin. Cancer Res. 15, 2507-2513
   Abstract »    Full Text »    PDF »
Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.
S. Nicholls, K. P. Piper, F. Mohammed, T. R. Dafforn, S. Tenzer, M. Salim, P. Mahendra, C. Craddock, P. van Endert, H. Schild, et al. (2009)
PNAS 106, 3889-3894
   Abstract »    Full Text »    PDF »
Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-{alpha}2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
J. M. Kirkwood, S. Lee, S. J. Moschos, M. R. Albertini, J. C. Michalak, C. Sander, T. Whiteside, L. H. Butterfield, and L. Weiner (2009)
Clin. Cancer Res. 15, 1443-1451
   Abstract »    Full Text »    PDF »
Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines.
C. L. Slingluff Jr, G. V. Yamshchikov, K. T. Hogan, S. C. Hibbitts, G. R. Petroni, E. A. Bissonette, J. W. Patterson, P. Y. Neese, W. W. Grosh, K. A. Chianese-Bullock, et al. (2008)
Ann. Surg. Oncol. 15, 3538-3549
   Abstract »    Full Text »    PDF »
TCR Complex-Activated CD8 Adhesion Function by Human T Cells.
J. C. Varghese and K. P. Kane (2008)
J. Immunol. 181, 6002-6009
   Abstract »    Full Text »    PDF »
Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting.
C. L. Slingluff Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, et al. (2007)
Clin. Cancer Res. 13, 6386-6395
   Abstract »    Full Text »    PDF »
Characterizing MHC-Associated Peptides by Mass Spectrometry.
L. J. Stern (2007)
J. Immunol. 179, 2667-2668
   Full Text »    PDF »
Human TCR-Binding Affinity is Governed by MHC Class Restriction.
D. K. Cole, N. J. Pumphrey, J. M. Boulter, M. Sami, J. I. Bell, E. Gostick, D. A. Price, G. F. Gao, A. K. Sewell, and B. K. Jakobsen (2007)
J. Immunol. 178, 5727-5734
   Abstract »    Full Text »    PDF »
Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response.
N. Anikeeva, T. Lebedeva, A. R. Clapp, E. R. Goldman, M. L. Dustin, H. Mattoussi, and Y. Sykulev (2006)
PNAS 103, 16846-16851
   Abstract »    Full Text »    PDF »
The ubiquitin-proteasome system plays essential roles in presenting an 8-mer CTL epitope expressed in APC to corresponding CD8+ T cells.
X. Duan, H. Hisaeda, J. Shen, L. Tu, T. Imai, B. Chou, S. Murata, T. Chiba, K. Tanaka, H. J. Fehling, et al. (2006)
Int. Immunol. 18, 679-687
   Abstract »    Full Text »    PDF »
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.
A. G. Brickner, A. M. Evans, J. K. Mito, S. M. Xuereb, X. Feng, T. Nishida, L. Fairfull, R. E. Ferrell, K. A. Foon, D. F. Hunt, et al. (2006)
Blood 107, 3779-3786
   Abstract »    Full Text »    PDF »
The Turnover Kinetics of Major Histocompatibility Complex Peptides of Human Cancer Cells.
E. Milner, E. Barnea, I. Beer, and A. Admon (2006)
Mol. Cell. Proteomics 5, 357-365
   Abstract »    Full Text »    PDF »
Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients.
R. M. Luiten, E. W.M. Kueter, W. Mooi, M. P.W. Gallee, E. M. Rankin, W. R. Gerritsen, S. M. Clift, W. J. Nooijen, P. Weder, W. F. van de Kasteele, et al. (2005)
J. Clin. Oncol. 23, 8978-8991
   Abstract »    Full Text »    PDF »
Rapid and Sensitive Identification of Major Histocompatibility Complex Class I-associated Tumor Peptides by Nano-LC MALDI MS/MS.
S. Hofmann, M. Gluckmann, S. Kausche, A. Schmidt, C. Corvey, R. Lichtenfels, C. Huber, C. Albrecht, M. Karas, and W. Herr (2005)
Mol. Cell. Proteomics 4, 1888-1897
   Abstract »    Full Text »    PDF »
Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity.
G. P. Linette, D. Zhang, F. S. Hodi, E. P. Jonasch, S. Longerich, C. P. Stowell, I. J. Webb, H. Daley, R. J. Soiffer, A. M. Cheung, et al. (2005)
Clin. Cancer Res. 11, 7692-7699
   Abstract »    Full Text »    PDF »
Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells.
V. Vignard, B. Lemercier, A. Lim, M.-C. Pandolfino, Y. Guilloux, A. Khammari, C. Rabu, K. Echasserieau, F. Lang, M.-L. Gougeon, et al. (2005)
J. Immunol. 175, 4797-4805
   Abstract »    Full Text »    PDF »
Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome.
I. J. M. de Vries, M. R. Bernsen, W. J. Lesterhuis, N. M. Scharenborg, S. P. Strijk, M.-J. P. Gerritsen, D. J. Ruiter, C. G. Figdor, C. J.A. Punt, and G. J. Adema (2005)
J. Clin. Oncol. 23, 5779-5787
   Abstract »    Full Text »    PDF »
Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma.
G. V. Yamshchikov, D. W. Mullins, C.-C. Chang, T. Ogino, L. Thompson, J. Presley, H. Galavotti, W. Aquila, D. Deacon, W. Ross, et al. (2005)
J. Immunol. 174, 6863-6871
   Abstract »    Full Text »    PDF »
Putting a Face to MHC Restriction.
P. Parham (2005)
J. Immunol. 174, 3-5
   Full Text »    PDF »
Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule.
C. L. Slingluff Jr, G. R. Petroni, G. V. Yamshchikov, S. Hibbitts, W. W. Grosh, K. A. Chianese-Bullock, E. A. Bissonette, D. L. Barnd, D. H. Deacon, J. W. Patterson, et al. (2004)
J. Clin. Oncol. 22, 4474-4485
   Abstract »    Full Text »    PDF »
DNA Array-Based Gene Profiling in Tumor Immunology.
S. Mocellin, E. Wang, M. Panelli, P. Pilati, and F. M. Marincola (2004)
Clin. Cancer Res. 10, 4597-4606
   Abstract »    Full Text »    PDF »
A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1.
K.-Y. Tsang, C. Palena, J. Gulley, P. Arlen, and J. Schlom (2004)
Clin. Cancer Res. 10, 2139-2149
   Abstract »    Full Text »    PDF »
Immunoproteomics: Mass Spectrometry-based Methods to Study the Targets of the Immune Response.
A. W. Purcell and J. J. Gorman (2004)
Mol. Cell. Proteomics 3, 193-208
   Abstract »    Full Text »    PDF »
Incomplete tolerance to the tumour-associated antigen MDM2.
F. Ramirez, Y. Ghani, and H. Stauss (2004)
Int. Immunol. 16, 327-334
   Abstract »    Full Text »    PDF »
Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells.
C. L. Slingluff Jr, G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, et al. (2003)
J. Clin. Oncol. 21, 4016-4026
   Abstract »    Full Text »    PDF »
Maturation of Dendritic Cells Is a Prerequisite for Inducing Immune Responses in Advanced Melanoma Patients.
I. J. M. de Vries, W. J. Lesterhuis, N. M. Scharenborg, L. P. H. Engelen, D. J. Ruiter, M.-J. P. Gerritsen, S. Croockewit, C. M. Britten, R. Torensma, G. J. Adema, et al. (2003)
Clin. Cancer Res. 9, 5091-5100
   Abstract »    Full Text »    PDF »
Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen.
G. Denkberg, A. Lev, L. Eisenbach, I. Benhar, and Y. Reiter (2003)
J. Immunol. 171, 2197-2207
   Abstract »    Full Text »    PDF »
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data.
D. L. Doolan, S. Southwood, D. A. Freilich, J. Sidney, N. L. Graber, L. Shatney, L. Bebris, L. Florens, C. Dobano, A. A. Witney, et al. (2003)
PNAS 100, 9952-9957
   Abstract »    Full Text »    PDF »
The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein.
E. Spierings, A. G. Brickner, J. A. Caldwell, S. Zegveld, N. Tatsis, E. Blokland, J. Pool, R. A. Pierce, S. Mollah, J. Shabanowitz, et al. (2003)
Blood 102, 621-629
   Abstract »    Full Text »    PDF »
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
V. Ramakrishna, M. M. Ross, M. Petersson, C. C. Gatlin, C. E. Lyons, C. L. Miller, H. E. Myers, M. McDaniel, L. R. Karns, R. Kiessling, et al. (2003)
Int. Immunol. 15, 751-763
   Abstract »    Full Text »    PDF »
Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides.
A. Admon, E. Barnea, and T. Ziv (2003)
Mol. Cell. Proteomics 2, 388-398
   Abstract »    Full Text »    PDF »
Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules.
M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu (2003)
J. Immunol. 170, 5317-5325
   Abstract »    Full Text »    PDF »
Immunomic analysis of human sarcoma.
S.-Y. Lee, Y. Obata, M. Yoshida, E. Stockert, B. Williamson, A. A. Jungbluth, Y.-T. Chen, L. J. Old, and M. J. Scanlan (2003)
PNAS 100, 2651-2656
   Abstract »    Full Text »    PDF »
Determinant Spreading Associated with Clinical Response in Dendritic Cell-based Immunotherapy for Malignant Melanoma.
L. H. Butterfield, A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H.-J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, et al. (2003)
Clin. Cancer Res. 9, 998-1008
   Abstract »    Full Text »    PDF »
Peptide Fine Specificity of Anti-Glycoprotein 100 CTL Is Preserved Following Transfer of Engineered TCR{alpha}{beta} Genes Into Primary Human T Lymphocytes.
N. Schaft, R. A. Willemsen, J. de Vries, B. Lankiewicz, B. W. L. Essers, J.-W. Gratama, C. G. Figdor, R. L. H. Bolhuis, R. Debets, and G. J. Adema (2003)
J. Immunol. 170, 2186-2194
   Abstract »    Full Text »    PDF »
Vaccine-induced CD8+ T-cell Responses to MAGE-3 Correlate with Clinical Outcome in Patients with Melanoma.
S. R. Reynolds, A. Zeleniuch-Jacquotte, R. L. Shapiro, D. F. Roses, M. N. Harris, D. Johnston, and J.-C. Bystryn (2003)
Clin. Cancer Res. 9, 657-662
   Abstract »    Full Text »    PDF »
Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies.
Z. Wang, Y. Zhang, H. Liu, E. Salati, M. Chiriva-Internati, and S. H. Lim (2003)
Blood 101, 955-960
   Abstract »    Full Text »    PDF »
Rational approaches to human cancer immunotherapy.
I. D. Davis, M. Jefford, P. Parente, and J. Cebon (2003)
J. Leukoc. Biol. 73, 3-29
   Abstract »    Full Text »    PDF »
Clonal Deletion of Simian Virus 40 Large T Antigen-Specific T Cells in the Transgenic Adenocarcinoma of Mouse Prostate Mice: An Important Role for Clonal Deletion in Shaping the Repertoire of T Cells Specific for Antigens Overexpressed in Solid Tumors.
X. Zheng, J.-X. Gao, H. Zhang, T. L. Geiger, Y. Liu, and P. Zheng (2002)
J. Immunol. 169, 4761-4769
   Abstract »    Full Text »    PDF »
Integrated Functional Genomics Approach for the Design of Patient-individual Antitumor Vaccines.
T. Weinschenk, C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K.-H. Bichler, D. Wernet, et al. (2002)
Cancer Res. 62, 5818-5827
   Abstract »    Full Text »    PDF »
Modification of a Tumor-Derived Peptide at an HLA-A2 Anchor Residue Can Alter the Conformation of the MHC-Peptide Complex: Probing with TCR-Like Recombinant Antibodies.
G. Denkberg, E. Klechevsky, and Y. Reiter (2002)
J. Immunol. 169, 4399-4407
   Abstract »    Full Text »    PDF »
Recruitment of CTL Activity by Tumor-Specific Antibody-Mediated Targeting of Single-Chain Class I MHC-Peptide Complexes.
A. Lev, H. Novak, D. Segal, and Y. Reiter (2002)
J. Immunol. 169, 2988-2996
   Abstract »    Full Text »    PDF »
Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans.
V. Dutoit, V. Rubio-Godoy, M. J. Pittet, A. Zippelius, P.-Y. Dietrich, F. A. Legal, P. Guillaume, P. Romero, J.-C. Cerottini, R. A. Houghten, et al. (2002)
J. Exp. Med. 196, 207-216
   Abstract »    Full Text »    PDF »
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.
G. Denkberg, C. J. Cohen, A. Lev, P. Chames, H. R. Hoogenboom, and Y. Reiter (2002)
PNAS 99, 9421-9426
   Abstract »    Full Text »    PDF »
Enhancing Immunogenicity of a CTL Epitope from Carcinoembryonic Antigen by Selective Amino Acid Replacements.
E. Huarte, P. Sarobe, J. Lu, N. Casares, J. J. Lasarte, J. Dotor, M. Ruiz, J. Prieto, E. Celis, and F. Borras-Cuesta (2002)
Clin. Cancer Res. 8, 2336-2344
   Abstract »    Full Text »    PDF »
Identification by Mass Spectrometry of CD8+-T-Cell Mycobacterium tuberculosis Epitopes within the Rv0341 Gene Product.
D. C. Flyer, V. Ramakrishna, C. Miller, H. Myers, M. McDaniel, K. Root, C. Flournoy, V. H. Engelhard, D. H. Canaday, J. A. Marto, et al. (2002)
Infect. Immun. 70, 2926-2932
   Abstract »    Full Text »    PDF »
T-Cell Responses against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund's Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants.
S. G. Schaed, V. M. Klimek, K. S. Panageas, C. M. Musselli, L. Butterworth, W.-J. Hwu, P. O. Livingston, L. Williams, J. J. Lewis, A. N. Houghton, et al. (2002)
Clin. Cancer Res. 8, 967-972
   Abstract »    Full Text »    PDF »
Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma.
M. Ayyoub, S. Stevanovic, U. Sahin, P. Guillaume, C. Servis, D. Rimoldi, D. Valmori, P. Romero, J.-C. Cerottini, H.-G. Rammensee, et al. (2002)
J. Immunol. 168, 1717-1722
   Abstract »    Full Text »    PDF »
Identification and Characterization of a Human Agonist Cytotoxic T-Lymphocyte Epitope of Human Prostate-specific Antigen.
H. Terasawa, K.-Y. Tsang, J. Gulley, P. Arlen, and J. Schlom (2002)
Clin. Cancer Res. 8, 41-53
   Abstract »    Full Text »    PDF »
Manipulation of Avidity to Improve Effectiveness of Adoptively Transferred CD8+ T Cells for Melanoma Immunotherapy in Human MHC Class I-Transgenic Mice.
T. N. J. Bullock, D. W. Mullins, T. A. Colella, and V. H. Engelhard (2001)
J. Immunol. 167, 5824-5831
   Abstract »    Full Text »    PDF »
Vaccines in oncology: background and clinical potential.
A C Armstrong and R E Hawkins (2001)
Br. J. Radiol. 74, 991-1002
   Abstract »    Full Text »    PDF »
Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice.
D. W. Mullins, T. N. J. Bullock, T. A. Colella, V. V. Robila, and V. H. Engelhard (2001)
J. Immunol. 167, 4853-4860
   Abstract »    Full Text »    PDF »
Identification of Helper T-Cell Epitopes That Encompass or Lie Proximal to Cytotoxic T-Cell Epitopes in the gp100 Melanoma Tumor Antigen.
H. Kobayashi, J. Lu, and E. Celis (2001)
Cancer Res. 61, 7577-7584
   Abstract »    Full Text »    PDF »
Phase I Trial of a Melanoma Vaccine with gp100280-288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes.
C. L. Slingluff Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al. (2001)
Clin. Cancer Res. 7, 3012-3024
   Abstract »    Full Text »    PDF »
Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity.
E. Keogh, J. Fikes, S. Southwood, E. Celis, R. Chesnut, and A. Sette (2001)
J. Immunol. 167, 787-796
   Abstract »    Full Text »    PDF »
Identification of Fibroblast Growth Factor-5 as an Overexpressed Antigen in Multiple Human Adenocarcinomas.
K.-i. Hanada, D. M. Perry-Lalley, G. A. Ohnmacht, M. P. Bettinotti, and J. C. Yang (2001)
Cancer Res. 61, 5511-5516
   Abstract »    Full Text »    PDF »
Generation of Cytotoxic T Lymphocytes against Native and Altered Peptides of Human Leukocyte Antigen-A*0201 Restricted Epitopes from the Human Epithelial Cell Adhesion Molecule.
A. Trojan, M. Witzens, J. L. Schultze, R. H. Vonderheide, S. Harig, A. M. Krackhardt, R. A. Stahel, and J. G. Gribben (2001)
Cancer Res. 61, 4761-4765
   Abstract »    Full Text »    PDF »
The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing.
A. G. Brickner, E. H. Warren, J. A. Caldwell, Y. Akatsuka, T. N. Golovina, A. L. Zarling, J. Shabanowitz, L. C. Eisenlohr, D. F. Hunt, V. H. Engelhard, et al. (2001)
J. Exp. Med. 193, 195-206
   Abstract »    Full Text »    PDF »
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.
S. Gnjatic, Y. Nagata, E. Jager, E. Stockert, S. Shankara, B. L. Roberts, G. P. Mazzara, S. Y. Lee, P. R. Dunbar, B. Dupont, et al. (2000)
PNAS 97, 10917-10922
   Abstract »    Full Text »    PDF »
Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen.
H. Kobayashi, M. Wood, Y. Song, E. Appella, and E. Celis (2000)
Cancer Res. 60, 5228-5236
   Abstract »    Full Text »
Identification of T Cell Ligands in a Library of Peptides Covalently Attached to HLA-DR4.
E. Boen, A. R. Crownover, M. McIlhaney, A. J. Korman, and J. Bill (2000)
J. Immunol. 165, 2040-2047
   Abstract »    Full Text »    PDF »
Identification on a Human Sarcoma of Two New Genes with Tumor-specific Expression.
V. Martelange, C. De Smet, E. De Plaen, C. Lurquin, and T. Boon (2000)
Cancer Res. 60, 3848-3855
   Abstract »    Full Text »
Functional Reconstitution of Class II MHC-Restricted T Cell Immunity Mediated by Retroviral Transfer of the {alpha}{beta} TCR Complex.
K. Fujio, Y. Misaki, K. Setoguchi, S. Morita, K. Kawahata, I. Kato, T. Nosaka, K. Yamamoto, and T. Kitamura (2000)
J. Immunol. 165, 528-532
   Abstract »    Full Text »    PDF »
Mass Spectrometric Identification of Mtb81, a Novel Serological Marker for Tuberculosis.
R. C. Hendrickson, J. F. Douglass, L. D. Reynolds, P. D. McNeill, D. Carter, S. G. Reed, and R. L. Houghton (2000)
J. Clin. Microbiol. 38, 2354-2361
   Abstract »    Full Text »
Tumor Antigens in Thoracic Malignancy.
S. M. Dubinett, R. K. Batra, P. W. Miller, and S. Sharma (2000)
Am. J. Respir. Cell Mol. Biol. 22, 524-527
   Full Text »
Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A3.
S. Yang, D. Kittlesen, C. L. Slingluff Jr., C. E. Vervaert, H. F. Seigler, and T. L. Darrow (2000)
J. Immunol. 164, 4204-4211
   Abstract »    Full Text »    PDF »
Self-Tolerance to the Murine Homologue of a Tyrosinase-derived Melanoma Antigen: Implications for Tumor Immunotherapy.
T. A. Colella, T. N.J. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard (2000)
J. Exp. Med. 191, 1221-1232
   Abstract »    Full Text »    PDF »
In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma.
G. P. Linette, S. Shankara, S. Longerich, S. Yang, R. Doll, C. Nicolette, F. I. Preffer, B. L. Roberts, and F. G. Haluska (2000)
J. Immunol. 164, 3402-3412
   Abstract »    Full Text »    PDF »
The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice.
T. N. J. Bullock, T. A. Colella, and V. H. Engelhard (2000)
J. Immunol. 164, 2354-2361
   Abstract »    Full Text »    PDF »
Deriving Quantitative Constraints on T Cell Selection from Data on the Mature T Cell Repertoire.
V. Detours, R. Mehr, and A. S. Perelson (2000)
J. Immunol. 164, 121-128
   Abstract »    Full Text »    PDF »
Cutting Edge: The HLA-A*0101-Restricted HY Minor Histocompatibility Antigen Originates from DFFRY and Contains a Cysteinylated Cysteine Residue as Identified by a Novel Mass Spectrometric Technique.
R. A. Pierce, E. D. Field, J. M. M. den Haan, J. A. Caldwell, F. M. White, J. A. Marto, W. Wang, L. M. Frost, E. Blokland, C. Reinhardus, et al. (1999)
J. Immunol. 163, 6360-6364
   Abstract »    Full Text »    PDF »
Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma.
F. Wang, E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen, and J. Weber (1999)
Clin. Cancer Res. 5, 2756-2765
   Abstract »    Full Text »    PDF »
Identification of Natural Antigenic Peptides of a Human Gastric Signet Ring Cell Carcinoma Recognized by HLA-A31-Restricted Cytotoxic T Lymphocytes.
K. Suzuki, H. Sahara, Y. Okada, T. Yasoshima, Y. Hirohashi, Y. Nabeta, I. Hirai, T. Torigoe, S. Takahashi, A. Matsuura, et al. (1999)
J. Immunol. 163, 2783-2791
   Abstract »    Full Text »    PDF »
Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas.
Y. Rongcun, F. Salazar-Onfray, J. Charo, K.-J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, et al. (1999)
J. Immunol. 163, 1037-1044
   Abstract »    Full Text »    PDF »
A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL.
S. Matsui, J. D. Ahlers, A. O. Vortmeyer, M. Terabe, T. Tsukui, D. P. Carbone, L. A. Liotta, and J. A. Berzofsky (1999)
J. Immunol. 163, 184-193
   Abstract »    Full Text »    PDF »
HLA-B15 Peptide Ligands Are Preferentially Anchored at Their C Termini.
K. R. Prilliman, K. W. Jackson, M. Lindsey, J. Wang, D. Crawford, and W. H. Hildebrand (1999)
J. Immunol. 162, 7277-7284
   Abstract »    Full Text »    PDF »
Vaccine therapy for cancer—fact or fiction?.
T.R.J. Evans and S.B. Kaye (1999)
QJM 92, 299-307
   Full Text »    PDF »
Covalent Linkage to {beta}2-Microglobulin Enhances the MHC Stability and Antigenicity of Suboptimal CTL Epitopes.
R. A. Uger, S. M. Chan, and B. H. Barber (1999)
J. Immunol. 162, 6024-6028
   Abstract »    Full Text »    PDF »
Inducing autoimmune disease to treat cancer.
D. M. Pardoll (1999)
PNAS 96, 5340-5342
   Full Text »    PDF »
Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination.
N. Maitre, J. M. Brown, M. Demcheva, J. R. Kelley, M. A. Lockett, J. Vournakis, and D. J. Cole (1999)
Clin. Cancer Res. 5, 1173-1182
   Abstract »    Full Text »    PDF »
Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/Kb Transgenic Mice.
Y. Men, I. Miconnet, D. Valmori, D. Rimoldi, J.-C. Cerottini, and P. Romero (1999)
J. Immunol. 162, 3566-3573
   Abstract »    Full Text »    PDF »
Cancer Vaccines.
T. F. Greten and E. M. Jaffee (1999)
J. Clin. Oncol. 17, 1047
   Abstract »    Full Text »    PDF »
Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells.
R. Pieper, R. E. Christian, M. I. Gonzales, M. I. Nishimura, G. Gupta, R. E. Settlage, J. Shabanowitz, S. A. Rosenberg, D. F. Hunt, and S. L. Topalian (1999)
J. Exp. Med. 189, 757-766
   Abstract »    Full Text »    PDF »
Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo.
S. Sarma, Y. Guo, Y. Guilloux, C. Lee, X.-F. Bai, and Y. Liu (1999)
J. Exp. Med. 189, 811-820
   Abstract »    Full Text »    PDF »
HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients.
S. R. Reynolds, E. Celis, A. Sette, R. Oratz, R. L. Shapiro, D. Johnston, M. Fotino, and J.-C. Bystryn (1998)
J. Immunol. 161, 6970-6976
   Abstract »    Full Text »    PDF »
Identification of New Melanoma Epitopes on Melanosomal Proteins Recognized by Tumor Infiltrating T Lymphocytes Restricted by HLA-A1, -A2, and -A3 Alleles.
Y. Kawakami, P. F. Robbins, X. Wang, J. P. Tupesis, M. R. Parkhurst, X. Kang, K. Sakaguchi, E. Appella, and S. A. Rosenberg (1998)
J. Immunol. 161, 6985-6992
   Abstract »    Full Text »    PDF »
Prevalence of Antibodies Against Proteins Derived From Leukemia Cells in Patients With Chronic Myeloid Leukemia.
M. Ling, Y.-J. Wen, and S. H. Lim (1998)
Blood 92, 4764-4770
   Abstract »    Full Text »    PDF »
The Same Natural Ligand Is Involved in Allorecognition of Multiple HLA-B27 Subtypes by a Single T Cell Clone: Role of Peptide and the MHC Molecule in Alloreactivity.
A. Paradela, M. Garcia-Peydro, J. Vazquez, D. Rognan, and J. A. Lopez de Castro (1998)
J. Immunol. 161, 5481-5490
   Abstract »    Full Text »    PDF »
High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo.
G. S. Ogg, P. Rod Dunbar, P. Romero, J.-L. Chen, and V. Cerundolo (1998)
J. Exp. Med. 188, 1203-1208
   Abstract »    Full Text »    PDF »
What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry.
K. P. Peterson, J. G. Pavlovich, D. Goldstein, R. Little, J. England, and C. M. Peterson (1998)
Clin. Chem. 44, 1951-1958
   Abstract »    Full Text »    PDF »
Perforin and IFN-{gamma} Are Involved in the Antitumor Effects of Antibody-Targeted Superantigens.
A. Rosendahl, K. Kristensson, J. Hansson, K. Riesbeck, T. Kalland, and M. Dohlsten (1998)
J. Immunol. 160, 5309-5313
   Abstract »    Full Text »    PDF »
Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development.
D. J. Kittlesen, L. W. Thompson, P. H. Gulden, J. C. A. Skipper, T. A. Colella, J. A. Shabanowitz, D. F. Hunt, V. H. Engelhard, and C. L. Slingluff Jr. (1998)
J. Immunol. 160, 2099-2106
   Abstract »    Full Text »    PDF »
Creating CTL Targets with Epitope-Linked {beta}2-Microglobulin Constructs.
R. A. Uger and B. H. Barber (1998)
J. Immunol. 160, 1598-1605
   Abstract »    Full Text »    PDF »
The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism.
J. M. den Haan, L. M. Meadows, W. Wang, J. Pool, E. Blokland, T. L. Bishop, C. Reinhardus, J. Shabanowitz, R. Offringa, D. F. Hunt, et al. (1998)
Science 279, 1054-1057
   Abstract »    Full Text »
A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes.
S. Shichijo, M. Nakao, Y. Imai, H. Takasu, M. Kawamoto, F. Niiya, D. Yang, Y. Toh, H. Yamana, and K. Itoh (1998)
J. Exp. Med. 187, 277-288
   Abstract »    Full Text »    PDF »
Class I-Restricted Alloreactive Cytotoxic T Lymphocytes Recognize a Complex Array of Specific MHC-Associated Peptides.
W. Wang, S. Man, P. H. Gulden, D. F. Hunt, and V. H. Engelhard (1998)
J. Immunol. 160, 1091-1097
   Abstract »    Full Text »    PDF »
Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity.
D. J. Morgan, H. T. C. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman (1998)
J. Immunol. 160, 643-651
   Abstract »    Full Text »    PDF »
Vaccine Trials for the Clinician: Prospects for Tumor Antigens.
S. Osanto (1997)
Oncologist 2, 284-299
   Abstract »    Full Text »    PDF »
Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: Utilization in design of syngeneic immunotherapy models.
N. Le Fur, W. K. Silvers, S. R. Kelsall, and B. Mintz (1997)
PNAS 94, 7561-7565
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)